RT Journal Article
SR Electronic
T1 COVID-19 vaccination and Guillain-Barré syndrome: analyses using the National Immunoglobulin Database
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.14.21267418
DO 10.1101/2021.12.14.21267418
A1 Keh, Ryan Y.S.
A1 Scanlon, Sophie
A1 Datta-Nemdharry, Preeti
A1 Donegan, Katherine
A1 Cavanagh, Sally
A1 Foster, Mark
A1 Skelland, David
A1 Palmer, James
A1 Machado, Pedro M.
A1 Carr, Aisling S.
A1 Lunn, Michael P.
A1 BPNS/ABN COVID-19 Vaccine GBS Study Group
YR 2021
UL http://medrxiv.org/content/early/2021/12/15/2021.12.14.21267418.abstract
AB Vaccination against viruses has rarely been associated with Guillain-Barré syndrome (GBS). An association with the COVID-19 vaccine is unknown. We performed a population-based study of National Health Service (NHS) data in England and a multicentre surveillance study from UK hospitals, to investigate the relationship between COVID-19 vaccination and GBS.Firstly, we present a retrospective analysis of every GBS patient in England in the National Immunoglobulin Database (NID) linked with their COVID-19 vaccination data. Cases of GBS identified in the National Immunoglobulin Database (NID) from 8 December 2021 to 8 July 2021 were linked to data from the National Immunisation Management System (NIMS) in England to identify exposure to a COVID-19 vaccine. For the NID/NIMS linked dataset, GBS cases temporally associated with vaccination within a 6-week risk window of any COVID-19 vaccine were identified. Secondly, we prospectively collected incident UK GBS cases from 1 January 2021 to 7 November 2021 in a separate UK multicentre surveillance database, regardless of vaccine exposure, with vaccine timings and GBS phenotypic data. For this multicentre UK surveillance dataset, we explored phenotypes of reported GBS cases to identify features of COVID-19 vaccine-associated GBS.996 GBS cases were recorded in the NID from January to October 2021. A spike of GBS cases above the 2016-2020 average occurred in March-April 2021. In England, among all cases of GBS, 198 occurred within 6 weeks of the first-dose COVID-19 vaccination (0.618 cases per 100,000 vaccinations, 176 ChAdOx1 nCoV-19 (AstraZeneca), 21 tozinameran (Pfizer), 1 mRNA-1273 (Moderna)). The excess of GBS occurs with a peak at 24 days; first-doses of ChAdOx1 nCoV-19 accounted for the excess. No excess was seen for second-dose vaccination. The absolute number of excess GBS cases was between 98-140 cases for first-dose ChAdOx1 nCoV-19 vaccination from January-July 2021. First-dose tozinameran and second-dose of any vaccination showed no excess GBS risk. 121 patients were reported in the separate multicentre surveillance dataset with no phenotypic or demographic differences identified between vaccinated and non-vaccinated GBS cases.Data from the linked NID/NIMS dataset suggest that first-dose ChAdOx1 nCoV-19vaccination is associated with an excess GBS risk of 0.576 (95%CI 0.481-0.691) cases per 100,000 doses. However, further data reported from a multicentre surveillance dataset suggest that no specific clinical features, including facial weakness, are associated with vaccination-related GBS compared to non-vaccinated cases. The pathogenic cause of the ChAdOx1 nCoV-19specific first dose link warrants further study.Competing Interest StatementCompeting interests P.M. Machado has received consulting speakers fees from Abbvie, BMS, Celgene, Eli Lilly, Galapagos, Janssen, MSD, Novartis, Orphazyme, Pfizer, Roche and UCB, all unrelated to this manuscript. The remaining authors report no competing interests.Funding StatementFunding No specific funding was received for this work. P.M. Machado, M.P. Lunn and A.S. Carr are supported by the National Institute for Health Research (NIH) University College London Hospitals (UCLH) Biomedical Research Centre (BRC). R.Y.S. Keh is funded by GBS-CIDP Foundation International.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UK Health Research Authority was consulted and advised that the study did not require review by an NHS Research Ethics Committee, as this was an analysis of previously collected, non-identifiable anonymised data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available on request to the corresponding author.ABNAssociation of British NeurologistsAESIAdverse Event of Special InterestBPNSBritish Peripheral Nerve SocietyDHSCDepartment of Health and Social CareGBSGuillain-Barré syndromeNHSNational Health ServiceNHSENational Health Service EnglandNIDNational Immunoglobulin DatabaseNIMSNational Immunisation Management SystemVIITVaccine-induced immune thrombotic thrombocytopenia